On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I...
What makes India a smart and viable setting for today’s clinical trials? Join us for the latest episode of Few & Far Between. Biorasi's ...
"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware...